

MAY 27 2003

I hereby certify that this correspondence is being  
mailed with the United States Postal Service as  
first class mail in an envelope addressed to: Mail  
Stop DD, Commissioner for Patents, PO Box 1450  
Alexandria, VA 22313 on May 21, 2003.

David Saliwanchik  
David R. Saliwanchik, Patent Attorney

1636  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
Examining Group 1636  
Patent Application  
Docket No. SPO-112  
Serial No. 09/762,842

#13

RECEIVED

MAY 28 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Examiner : Celine X Qian, Ph.D.  
Art Unit : 1636  
Applicants : Murasugi Akira, Asami Yukio, Kido Isao and Kumai Hideshi  
Serial No. : 09/762,842  
Filed : February 12, 2001  
Conf. No. : 1096  
For : High Level Secretory Expression System of Intact MK Family Protein

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

The undersigned hereby certifies that the items of information contained in this statement were cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

The Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.


Respectfully submitted,



David R. Saliwanchik  
Patent Attorney  
Registration No. 31,794  
Phone No.: 352-375-8100  
Address : 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

DRS/la

Enclosures: Form PTO/SB/08; and  
Copies of references cited therein.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

### Complete if Known

Application Number	09/762,842
Filing Date	February 12, 2001
First Named Inventor	Murasugi Akira
Group Art Unit	1636
Examiner Name	Celine X Qian, Ph.D.
Attorney Docket Number	SPO-112

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	MILNER, PETER G., SHAH, DULARI, VEILE, ROSALIE, DONIS-KELLER, HELEN and KUMAR, VIJAYA (1992) "Cloning, Nucleotide Sequence, and Chromosome Localization of the Human Pleiotrophin Gene" <i>Biochemistry</i> 31(48):12023-12028.	
	R2	Database Geneseq Accession No. AAT12736, 1994.	
	R3		RECEIVED
	R4		MAY 28 2003
	R5		TECH CENTER 1600/2900
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.